George Demetri
Director/Board Member bei American Association for Cancer Research
Profil
Founder of IDRx, Inc., George D.
Demetri currently is Senior Advisor at Arsenal Capital Management LP.
Dr. Demetri is also on the board of American Association for Cancer Research and Blueprint Medicines Corp.
and Senior Vice President-Experimental Therapeutics at Dana-Farber Cancer Institute, Inc. and Professor & Director-Ludwig Center at Harvard Medical School.
In the past he held the position of Associate Editor-Publications at American Society of Clinical Oncology.
George D.
Demetri received an undergraduate degree from Harvard College and a doctorate from Stanford University School of Medicine.
Aktive Positionen von George Demetri
Unternehmen | Position | Beginn |
---|---|---|
Harvard Medical School | Corporate Officer/Principal | 01.01.1988 |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Director/Board Member | - |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Arsenal Capital Management LP
Arsenal Capital Management LP Investment ManagersFinance Arsenal Capital Management LP (Arsenal Capital) is a private equity subsidiary of Arsenal Capital Group LLC founded in 2000 by Terrence M. Mullen and Jeffrey B. Kovach. The firm is headquartered in New York. | Consultant / Advisor | - |
Ehemalige bekannte Positionen von George Demetri
Unternehmen | Position | Ende |
---|---|---|
TRANSLATE BIO, INC. | Director/Board Member | 14.09.2021 |
MERRIMACK PHARMACEUTICALS, INC. | Director/Board Member | 01.09.2019 |
IDRx, Inc.
IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Founder | - |
PRECIPIO, INC. | Director/Board Member | - |
BLUEPRINT MEDICINES CORPORATION | Director/Board Member | - |
Ausbildung von George Demetri
Stanford University School of Medicine | Doctorate Degree |
Harvard College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
BLUEPRINT MEDICINES CORPORATION | Health Technology |
PRECIPIO, INC. | Health Services |
Private Unternehmen | 6 |
---|---|
Translate Bio, Inc.
Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Health Services |
Arsenal Capital Management LP
Arsenal Capital Management LP Investment ManagersFinance Arsenal Capital Management LP (Arsenal Capital) is a private equity subsidiary of Arsenal Capital Group LLC founded in 2000 by Terrence M. Mullen and Jeffrey B. Kovach. The firm is headquartered in New York. | Finance |
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Health Services |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Commercial Services |
IDRx, Inc.
IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Commercial Services |